Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
LNCaP model of human prostatic carcinoma.
Hormonal manipulations show that, regardless of sex, the frequency of tumor development correlates with serum androgen levels, however, the rate of the tumor growth is independent of the gender of hormonal status of the host. Expand
Purification of a human prostate specific antigen.
- M. Wang, L. Valenzuela, G. Murphy, T. M. Chu
- Chemistry, Medicine
- Investigative urology
- 1 September 1979
This report presents the first demonstration of the purification of a prostate-specific antigen that does not represent prostatic acid phosphatase and shows a single protein band on analytical polyacrylamide gel electrophoresis and isoelectric focusing. Expand
American Cancer Society guideline for the early detection of prostate cancer: Update 1997
- A. V. von Eschenbach, R. Ho, G. Murphy, M. Cunningham, N. Lins
- CA: a cancer journal for clinicians
- 1 September 1997
This guideline for the early detection of prostate cancer is based on knowledge gained by a critical analysis of experience since the original version of 1992 and is offered to health care professionals seeking to provide optimal care to asymptomatic men at risk for prostate cancer. Expand
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Highly significant association between diagnosed prostatic cancer and circulating molecules expressing the epitope reactive with MoAb 7E11-C5 was established and suggested that patients with positive ELISA test are more likely to be in progression, than those who are negative. Expand
Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen
Investigations involving the role of T‐cell immunity in the clearance of neoplastic cells are now available and development of T-cell immunotherapy may give a new approach to the treatment of advanced metastatic prostate cancer. Expand
Prostate antigen: A new potential marker for prostatic cancer
- M. Wang, L. Papsidero, M. Kuriyama, L. Valenzuela, G. Murphy, T. M. Chu
- Biology, Medicine
- The Prostate
The prostate‐specific antigen, distinct from acid phosphatase, was identified by immunologic procedures in prostate tissues and seminal plasma, as well as in sera of patients with prostatic cancer and of nude mice bearing human prostatic tumor. Expand
Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer
This work attempted to evaluate the potential of circulating IL‐6 levels as a marker of disease progression and found it to be a candidate mediator of morbidity in patients with metastatic disease. Expand
American Joint Committee on Cancer prognostic factors consensus conference.
Recommendations were made regarding the emerging sentinel lymph node technique, the need for an increased use of histopathology in the staging of breast and ovarian carcinomas, and the use of additional histologic staining techniques for the detection of "micrometastases" in lymph nodes. Expand
Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms
This is the first immununohistochemical marker for prostate gland epithelium which does not represent prostatic acid phosphatase and is likely to be a diagnostic histologic marker for tumors of prostatic origin. Expand
A prostate antigen in sera of prostatic cancer patients.
Sera from 175 patients with nonprostatic cancers, including those with late-stage disease of the breast, lung, colon, rectum, stomach, and pancreas, were antigen negative as were 20 samples each from normal adults and age-matched males. Expand